Meta-analysis evaluating denosumab and zoledronic acid for remedy of bone metastases in sufferers with superior stable tumours.
Eur J Most cancers Care (Engl). 2017 Nov;26(6):
Authors: Zheng GZ, Chang B, Lin FX, Xie D, Hu QX, Yu GY, Du SX, Li XD
The aim of this meta-analysis was to guage the efficacy of denosumab, in contrast with zoledronic acid (ZA), in delaying skeletal-related occasions (SREs) and enhancing general survival in sufferers with superior stable tumours and bone metastases. A scientific literature search of a number of digital databases, together with PubMed, Medline, Embase, the Cochrane Library, CKNI and Net of Science with Convention Proceedings, was carried out. Solely randomised managed trials assessing denosumab compared with ZA, in sufferers with superior stable tumours and metastatic-stage illness, had been included. The first final result was the time to first SRE. The chance of growing subsequent on-study SREs and general survival had been additionally evaluated. Three randomised managed trials with a complete of 5,544 sufferers with superior stable tumours and bone metastases had been included within the meta-analysis. There have been 2,776 sufferers handled with denosumab and a couple of,768 handled with ZA. The pooled evaluation confirmed that denosumab was superior to ZA in delaying time to first on-study SRE (odds ratio [OR]: Zero.82; 95% CI: Zero.75-Zero.89, p < Zero.0001) and a number of SREs (threat ratio: Zero.81; 95% CI: Zero.74-Zero.88, p < Zero.0001). Nevertheless, no important distinction was present in general survival enchancment between denosumab and ZA (OR: 1.02; 95% CI: Zero.91-1.15, p = Zero.71). This meta-analysis signifies that denosumab is superior to ZA in delaying SREs for sufferers with bone metastases. No important distinction was noticed between denosumab and ZA, concerning general survival. We assist denosumab as a possible novel remedy possibility for the administration of bone metastases in superior stable tumours.
PMID: 27430483 [PubMed – indexed for MEDLINE]